The ADC bladder cancer drug Padcev is seeking reimbursement as both monotherapy and combination therapy in Korea.

According to industry sources, Astellas Pharma Korea recently submitted reimbursement applications for Padcev (enfortumab vedotin) as monotherapy and combination therapy with PD-1 inhibitor Keytruda (pembrolizumab) in the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have received prior treatment with PD-1 or PD-L1 inhibitors and platinum-based chemotherapy agents.

The monotherapy option passed the Health Insurance Review and Assessment Service's Cancer Disease Deliberation Committee review in February this year, but the application